688217 睿昂基因
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)0.9810.8424.4346.1656.171
总资产报酬率 ROA (%)0.8920.7453.9855.7055.662
投入资产回报率 ROIC (%)0.9440.8134.3236.0196.057

边际利润分析
销售毛利率 (%)75.11373.21160.80073.10871.843
营业利润率 (%)2.232-2.51316.90112.52914.061
息税前利润/营业总收入 (%)1.328-5.07715.36114.43715.279
净利润/营业总收入 (%)4.308-1.86115.53613.77513.624

收益指标分析
经营活动净收益/利润总额(%)156.0981.691124.44966.95190.921
价值变动净收益/利润总额(%)29.211-32.0324.3338.3910.551
营业外收支净额/利润总额(%)6.56730.983-0.32314.1160.059

偿债能力分析
流动比率 (X)11.60311.9676.93116.63710.370
速动比率 (X)10.37810.5446.33315.5239.649
资产负债率 (%)7.0047.32510.3755.3687.015
带息债务/全部投入资本 (%)2.1302.2720.5330.2240.822
股东权益/带息债务 (%)4,527.8064,222.67418,236.10843,618.02411,831.649
股东权益/负债合计 (%)1,302.5041,236.560833.1971,747.3541,295.339
利息保障倍数 (X)-1.2513.534-10.337-95.10012.639

营运能力分析
应收账款周转天数 (天)259.507308.851177.977202.927206.701
存货周转天数 (天)303.120298.23698.723147.966142.071